Is MPLT or OTLK more profitable?

Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A N/A N/A Oncobiologics N/A N/A -291.28%

Does the media refer more to MPLT or OTLK?

In the previous week, Maplight Therapeutics had 5 more articles in the media than Oncobiologics. MarketBeat recorded 24 mentions for Maplight Therapeutics and 19 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.96 beat Maplight Therapeutics' score of 0.35 indicating that Oncobiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 7 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Oncobiologics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is STTK or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -60.73% -55.75% Oncobiologics N/A N/A -291.28%

Which has higher earnings & valuation, OTLK or ALT?

Oncobiologics has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncobiologics $1.35M 100.49 -$62.42M -$1.17 N/A Altimmune $40K 14,585.25 -$88.09M -$0.93 N/A

Is OTLK or ALT more profitable?

Oncobiologics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Oncobiologics' return on equity of 0.00% beat Altimmune's return on equity. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -291.28% Altimmune -214,860.98% -42.57% -35.57%

Does the media prefer OTLK or ALT?

In the previous week, Oncobiologics had 4 more articles in the media than Altimmune. MarketBeat recorded 19 mentions for Oncobiologics and 15 mentions for Altimmune. Oncobiologics' average media sentiment score of 0.96 beat Altimmune's score of -0.32 indicating that Oncobiologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 7 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer OTLK or FDMT?

In the previous week, Oncobiologics had 9 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 19 mentions for Oncobiologics and 10 mentions for 4D Molecular Therapeutics. Oncobiologics' average media sentiment score of 0.96 beat 4D Molecular Therapeutics' score of 0.74 indicating that Oncobiologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRME or OTLK?

In the previous week, Oncobiologics had 15 more articles in the media than Prime Medicine. MarketBeat recorded 19 mentions for Oncobiologics and 4 mentions for Prime Medicine. Oncobiologics' average media sentiment score of 0.96 beat Prime Medicine's score of 0.69 indicating that Oncobiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncobiologics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oncobiologics (OTLK) Competitors

$0.91 -0.06 (-6.51%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$0.92 +0.01 (+0.55%)

As of 08/3/2026 07:58 PM Eastern

Compare

OTLK vs. MPLT, STTK, ALT, FDMT, and PRME

Should you buy Oncobiologics stock or one of its competitors? MarketBeat compares Oncobiologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oncobiologics include Maplight Therapeutics (MPLT), Shattuck Labs (STTK), Altimmune (ALT), 4D Molecular Therapeutics (FDMT), and Prime Medicine (PRME). These companies are all part of the "biotechnology" industry.

How does Oncobiologics compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Oncobiologics	N/A	N/A	-291.28%

Maplight Therapeutics presently has a consensus target price of $34.42, indicating a potential upside of 174.24%. Oncobiologics has a consensus target price of $4.65, indicating a potential upside of 409.31%. Given Oncobiologics' higher probable upside, analysts plainly believe Oncobiologics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.00
Oncobiologics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

11.2% of Oncobiologics shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Oncobiologics has higher revenue and earnings than Maplight Therapeutics. Oncobiologics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Oncobiologics	$1.35M	100.49	-$62.42M	-$1.17	N/A

In the previous week, Maplight Therapeutics had 5 more articles in the media than Oncobiologics. MarketBeat recorded 24 mentions for Maplight Therapeutics and 19 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.96 beat Maplight Therapeutics' score of 0.35 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	7 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncobiologics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Maplight Therapeutics beats Oncobiologics on 7 of the 13 factors compared between the two stocks.

How does Oncobiologics compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

In the previous week, Oncobiologics had 19 more articles in the media than Shattuck Labs. MarketBeat recorded 19 mentions for Oncobiologics and 0 mentions for Shattuck Labs. Oncobiologics' average media sentiment score of 0.96 beat Shattuck Labs' score of 0.00 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Shattuck Labs	Neutral
Oncobiologics	Positive

Shattuck Labs presently has a consensus price target of $12.63, suggesting a potential upside of 73.18%. Oncobiologics has a consensus price target of $4.65, suggesting a potential upside of 409.31%. Given Oncobiologics' higher probable upside, analysts clearly believe Oncobiologics is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Oncobiologics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Oncobiologics' return on equity of 0.00% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Oncobiologics	N/A	N/A	-291.28%

Shattuck Labs has higher earnings, but lower revenue than Oncobiologics. Shattuck Labs is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	559.00	-$48.81M	-$0.63	N/A
Oncobiologics	$1.35M	100.49	-$62.42M	-$1.17	N/A

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 1.8% of Oncobiologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Shattuck Labs has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market.

Summary

Shattuck Labs beats Oncobiologics on 9 of the 15 factors compared between the two stocks.

How does Oncobiologics compare to Altimmune?

Oncobiologics (NASDAQ:OTLK) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Oncobiologics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Oncobiologics' return on equity of 0.00% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
Altimmune	-214,860.98%	-42.57%	-35.57%

Oncobiologics has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	100.49	-$62.42M	-$1.17	N/A
Altimmune	$40K	14,585.25	-$88.09M	-$0.93	N/A

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 1.8% of Oncobiologics shares are held by company insiders. Comparatively, 1.6% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Oncobiologics currently has a consensus target price of $4.65, suggesting a potential upside of 409.31%. Altimmune has a consensus target price of $15.71, suggesting a potential upside of 423.81%. Given Altimmune's stronger consensus rating and higher possible upside, analysts plainly believe Altimmune is more favorable than Oncobiologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Oncobiologics has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market. Comparatively, Altimmune has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

In the previous week, Oncobiologics had 4 more articles in the media than Altimmune. MarketBeat recorded 19 mentions for Oncobiologics and 15 mentions for Altimmune. Oncobiologics' average media sentiment score of 0.96 beat Altimmune's score of -0.32 indicating that Oncobiologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncobiologics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	7 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Oncobiologics beats Altimmune on 9 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to 4D Molecular Therapeutics?

Oncobiologics (NASDAQ:OTLK) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Oncobiologics had 9 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 19 mentions for Oncobiologics and 10 mentions for 4D Molecular Therapeutics. Oncobiologics' average media sentiment score of 0.96 beat 4D Molecular Therapeutics' score of 0.74 indicating that Oncobiologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncobiologics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
4D Molecular Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oncobiologics presently has a consensus price target of $4.65, suggesting a potential upside of 409.31%. 4D Molecular Therapeutics has a consensus price target of $30.67, suggesting a potential upside of 203.93%. Given Oncobiologics' higher possible upside, equities research analysts clearly believe Oncobiologics is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Oncobiologics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. Oncobiologics' return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

Oncobiologics has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.73, meaning that its share price is 173% more volatile than the broader market.

Oncobiologics has higher earnings, but lower revenue than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	100.49	-$62.42M	-$1.17	N/A
4D Molecular Therapeutics	$85.21M	6.19	-$140.11M	-$2.57	N/A

Summary

Oncobiologics beats 4D Molecular Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Oncobiologics compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Prime Medicine presently has a consensus price target of $7.53, suggesting a potential upside of 168.02%. Oncobiologics has a consensus price target of $4.65, suggesting a potential upside of 409.31%. Given Oncobiologics' higher probable upside, analysts clearly believe Oncobiologics is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Oncobiologics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Oncobiologics has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Oncobiologics' return on equity of 0.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Oncobiologics	N/A	N/A	-291.28%

Oncobiologics has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.03M	125.81	-$201.14M	-$1.23	N/A
Oncobiologics	$1.35M	100.49	-$62.42M	-$1.17	N/A

Prime Medicine has a beta of 2.26, suggesting that its stock price is 126% more volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market.

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 16.0% of Prime Medicine shares are held by company insiders. Comparatively, 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Oncobiologics had 15 more articles in the media than Prime Medicine. MarketBeat recorded 19 mentions for Oncobiologics and 4 mentions for Prime Medicine. Oncobiologics' average media sentiment score of 0.96 beat Prime Medicine's score of 0.69 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncobiologics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Prime Medicine beats Oncobiologics on 9 of the 17 factors compared between the two stocks.

Get Oncobiologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OTLK vs. The Competition

Export

Metric	Oncobiologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$145.11M	$3.55B	$6.86B	$12.44B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-0.78	7.29	280.74	24.99
Price / Sales	100.49	1,264.35	588.16	90.43
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	-1.52	16.89	11.02	6.21
Net Income	-$62.42M	-$12.54M	$3.48B	$347.49M
7 Day Performance	1.00%	0.31%	0.81%	1.29%
1 Month Performance	-37.03%	-7.40%	-4.15%	-3.59%
1 Year Performance	-54.58%	47.13%	61.47%	18.38%

Oncobiologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OTLK Oncobiologics	4.1679 of 5 stars	$0.91 -6.5%	$4.65 +409.3%	-52.7%	$145.11M	$1.35M	N/A	20	Analyst Upgrade
MPLT Maplight Therapeutics	3.1771 of 5 stars	$13.37 -4.7%	$34.42 +157.5%	N/A	$567.91M	N/A	N/A	109	Analyst Downgrade
STTK Shattuck Labs	2.327 of 5 stars	$7.18 -0.2%	$12.63 +75.9%	+895.9%	$549.96M	$1M	N/A	100
ALT Altimmune	2.015 of 5 stars	$2.81 -5.9%	$15.71 +460.2%	-16.9%	$545.31M	$36K	N/A	50	Positive News Upcoming Earnings Gap Up
FDMT 4D Molecular Therapeutics	3.319 of 5 stars	$10.27 +1.9%	$30.67 +198.7%	+57.2%	$536.72M	$88.24M	N/A	120	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OTLK) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncobiologics (OTLK) Competitors

OTLK vs. MPLT, STTK, ALT, FDMT, and PRME

How does Oncobiologics compare to Maplight Therapeutics?

Summary

How does Oncobiologics compare to Shattuck Labs?

Summary

How does Oncobiologics compare to Altimmune?

Summary

How does Oncobiologics compare to 4D Molecular Therapeutics?

Summary

How does Oncobiologics compare to Prime Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK vs. The Competition

Oncobiologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncobiologics (OTLK) Competitors

OTLK vs. MPLT, STTK, ALT, FDMT, and PRME

How does Oncobiologics compare to Maplight Therapeutics?

Is MPLT or OTLK more profitable?

Do analysts prefer MPLT or OTLK?

Do institutionals & insiders believe in MPLT or OTLK?

Which has better earnings and valuation, MPLT or OTLK?

Does the media refer more to MPLT or OTLK?

Summary

How does Oncobiologics compare to Shattuck Labs?

Does the media refer more to STTK or OTLK?

Do analysts recommend STTK or OTLK?

Is STTK or OTLK more profitable?

Which has stronger earnings & valuation, STTK or OTLK?

Do institutionals and insiders hold more shares of STTK or OTLK?

Which has more volatility & risk, STTK or OTLK?

Summary

How does Oncobiologics compare to Altimmune?

Is OTLK or ALT more profitable?

Which has higher earnings & valuation, OTLK or ALT?

Do institutionals & insiders hold more shares of OTLK or ALT?

Do analysts rate OTLK or ALT?

Which has more risk & volatility, OTLK or ALT?

Does the media prefer OTLK or ALT?

Summary

How does Oncobiologics compare to 4D Molecular Therapeutics?

Do insiders & institutionals hold more shares of OTLK or FDMT?

Does the media prefer OTLK or FDMT?

Do analysts rate OTLK or FDMT?

Is OTLK or FDMT more profitable?

Which has more volatility & risk, OTLK or FDMT?

Which has preferable valuation & earnings, OTLK or FDMT?

Summary

How does Oncobiologics compare to Prime Medicine?

Do analysts rate PRME or OTLK?

Is PRME or OTLK more profitable?

Which has higher earnings and valuation, PRME or OTLK?

Which has more volatility and risk, PRME or OTLK?

Do insiders and institutionals have more ownership in PRME or OTLK?

Does the media refer more to PRME or OTLK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK vs. The Competition

Oncobiologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools